(Q44120247)

30 November 2017

title

Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers (English)

1 reference

30 November 2017

1 reference

Laurian Vlase

1

1 reference

30 November 2017

Adina Popa

2

1 reference

30 November 2017

Maria Neag

3

1 reference

30 November 2017

Dana Muntean

4

1 reference

30 November 2017

Marcela Achim

5

1 reference

30 November 2017

Sorin Emilian Leucuţa

6

1 reference

30 November 2017

publication date

1 January 2012

1 reference

Clinical and Experimental Pharmacology and Physiology

30 November 2017

published in

1 reference

30 November 2017

volume

39

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

9-12

1 reference

Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Rifampin reduces plasma concentrations and effects of zolpidem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Overview of the pharmacokinetics of fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Central nervous system side effects associated with zolpidem treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05625.X

10.1111/J.1440-1681.2011.05625.X

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lu7go56rrnfqxlgtt62l2jrlhm

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_lu7go56rrnfqxlgtt62l2jrlhm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lu7go56rrnfqxlgtt62l2jrlhm

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/lu7go56rrnfqxlgtt62l2jrlhm

1 reference